NASDAQ:IART Integra LifeSciences (IART) Stock Price, News & Analysis $15.10 -0.02 (-0.13%) Closing price 04:00 PM EasternExtended Trading$15.10 0.00 (-0.03%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Integra LifeSciences Stock (NASDAQ:IART) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Integra LifeSciences alerts:Sign Up Key Stats Today's Range$14.83▼$15.3950-Day Range$8.90▼$15.3952-Week Range$8.70▼$16.49Volume814,610 shsAverage Volume1.23 million shsMarket Capitalization$1.17 billionP/E RatioN/ADividend YieldN/APrice Target$12.75Consensus RatingReduce Company Overview Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices. Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts. Key additions to its portfolio include the integration of Derma Sciences’ regenerative wound care products and the acquisition of Johnson & Johnson’s Codman neurosurgery business. These strategic moves have broadened the company’s offerings across dura repair, nerve regeneration and orthopedic extremities. Integra’s technologies serve a diverse set of clinical settings, including hospitals, outpatient surgical centers and specialty clinics. With a presence in North America, Europe, Asia-Pacific and Latin America, the company maintains manufacturing and distribution operations on multiple continents to support regional product demand and regulatory compliance. Its global footprint allows for collaboration with healthcare professionals on product development and clinical training initiatives. The company is guided by a management team with extensive experience in medical device innovation, regulatory affairs and commercial operations. Integra continues to invest in research and development, pursuing new applications in tissue engineering and minimally invasive surgery while maintaining a focus on improving patient outcomes and supporting healthcare providers worldwide.AI Generated. May Contain Errors. Read More Integra LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks20th Percentile Overall ScoreIART MarketRank™: Integra LifeSciences scored higher than 20% of companies evaluated by MarketBeat, and ranked 790th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.8 / 5Analyst RatingReduce Consensus RatingIntegra LifeSciences has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 3 hold ratings, and 3 sell ratings.Downside RiskIntegra LifeSciences has a consensus price target of $12.75, representing about 15.6% downside from its current price of $15.10.Amount of Analyst CoverageIntegra LifeSciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Integra LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings Growth5.33% Earnings GrowthEarnings for Integra LifeSciences are expected to grow by 5.33% in the coming year, from $2.44 to $2.57 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Integra LifeSciences is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Integra LifeSciences is -2.34, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioIntegra LifeSciences has a PEG Ratio of 1.05. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioIntegra LifeSciences has a P/B Ratio of 1.13. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Integra LifeSciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.47% of the float of Integra LifeSciences has been sold short.Short Interest Ratio / Days to CoverIntegra LifeSciences has a short interest ratio ("days to cover") of 12.59, which indicates bearish sentiment.Change versus previous monthShort interest in Integra LifeSciences has recently increased by 1.84%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntegra LifeSciences does not currently pay a dividend.Dividend GrowthIntegra LifeSciences does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.34 News SentimentIntegra LifeSciences has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Integra LifeSciences this week, compared to 3 articles on an average week.Search Interest3 people have searched for IART on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Integra LifeSciences to their MarketBeat watchlist in the last 30 days. Company Ownership0.9 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Integra LifeSciences insiders have not sold or bought any company stock.Percentage Held by Insiders3.84% of the stock of Integra LifeSciences is held by insiders.Percentage Held by Institutions84.78% of the stock of Integra LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Integra LifeSciences' insider trading history. Receive IART Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Integra LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IART Stock News HeadlinesIntegra LifeSciences Holdings Corporation (NASDAQ:IART) Given Consensus Recommendation of "Reduce" by BrokeragesMay 21 at 3:33 AM | americanbankingnews.comA Look At Integra LifeSciences Holdings (IART) Valuation After Recent Share Price MomentumMay 20 at 11:57 PM | finance.yahoo.comYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.May 22 at 1:00 AM | Profits Run (Ad)Why Integra LifeSciences (IART) is a top momentum stock for the long termMay 18, 2026 | msn.comIntegra LifeSciences (IART) Is Up 6.4% After Essig Returns As CEO With Reaffirmed 2026 GuidanceMay 15, 2026 | finance.yahoo.comIntegra LifeSciences Holdings Corporation (IART) Presents at Bank of America Global Healthcare Conference 2026 TranscriptMay 12, 2026 | seekingalpha.comIntegra LifeSciences Leadership Shift And ESOP Move Highlight Valuation GapMay 10, 2026 | finance.yahoo.comIntegra LifeSciences Holdings Corporation 2026 Q1 - Results - Earnings Call PresentationMay 8, 2026 | seekingalpha.comSee More Headlines IART Stock Analysis - Frequently Asked Questions How have IART shares performed this year? Integra LifeSciences' stock was trading at $12.42 on January 1st, 2026. Since then, IART shares have increased by 21.6% and is now trading at $15.10. How were Integra LifeSciences' earnings last quarter? Integra LifeSciences Holdings Corporation (NASDAQ:IART) posted its quarterly earnings results on Tuesday, May, 5th. The life sciences company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.41 by $0.13. The firm's quarterly revenue was up 2.4% compared to the same quarter last year. Read the conference call transcript. When did Integra LifeSciences' stock split? Integra LifeSciences's stock split before market open on Tuesday, January 3rd 2017.The 2-1 split was announced on Thursday, December 22nd 2016. The newly issued shares were issued to shareholders after the closing bell on Wednesday, December 21st 2016. An investor that had 100 shares of stock prior to the split would have 200 shares after the split. Does Integra LifeSciences have any subsidiaries? Integra LifeSciences subsidiaries include these companies: ACell Inc, Rebound Therapeutics, Arkis BioSciences, Codman Neuro, TGX Medical Systems, Derma Sciences, Tekmed Instruments S.p.A, and others. Who are Integra LifeSciences' major shareholders? Integra LifeSciences' top institutional investors include Paradigm Capital Management Inc. NY (5.16%), Dimensional Fund Advisors LP (3.56%), Bank of America Corp DE (1.82%) and Systematic Financial Management LP (1.36%). Insiders that own company stock include Stuart Essig, Michael J Mcbreen, Jeffrey A Graves and Witte Jan De. View institutional ownership trends. How do I buy shares of Integra LifeSciences? Shares of IART stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Integra LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Integra LifeSciences investors own include Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Netflix (NFLX), JPMorgan Chase & Co. (JPM), Tesla (TSLA) and Home Depot (HD). Company Calendar Last Earnings5/05/2026Today5/22/2026Next Earnings (Estimated)7/30/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History May 25 Aug 25 Nov 25 Feb 26 May 26 For the last 2 weeks, IART's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED INSTRUMENTS Sub-IndustryHealth Care Equipment Current SymbolNASDAQ:IART CIK917520 Webwww.integralife.com Phone(609) 275-0500Fax609-750-4277Employees4,427Year Founded1989Price Target and Rating Average Price Target for Integra LifeSciences$12.75 High Price Target$15.00 Low Price Target$11.00 Potential Upside/Downside-15.6%Consensus RatingReduce Rating Score (0-4)1.50 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($6.46) Trailing P/E RatioN/A Forward P/E Ratio6.19 P/E Growth1.05Net Income-$516.47 million Net Margins-30.15% Pretax Margin-32.59% Return on Equity17.42% Return on Assets5.00% Debt Debt-to-Equity Ratio1.75 Current Ratio3.38 Quick Ratio1.95 Sales & Book Value Annual Sales$1.64 billion Price / Sales0.72 Cash Flow$4.22 per share Price / Cash Flow3.58 Book Value$13.40 per share Price / Book1.13Miscellaneous Outstanding Shares77,800,000Free Float74,810,000Market Cap$1.17 billion OptionableOptionable Beta1.08 Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:IART) was last updated on 5/22/2026 by MarketBeat.com Staff. From Our PartnersOne algorithm, 17 years, nearly 2,000% total returnsA physicist in Dublin claims his AI algorithm has beaten the market for 17 consecutive years - with nearly 2,0...Porter & Company | SponsoredSpaceX controls two-thirds of all satellites - and it is about to go publicSpaceX is targeting an IPO on June 11th, with trading set to begin June 12th and the roadshow kicking off June...NXT Wave Research | SponsoredYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...Profits Run | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredGoldman Sachs just told you what to buy (most people missed it)Goldman Sachs just revealed that 40% of AI data centers will be crippled by electricity shortages by 2027 - no...Behind the Markets | SponsoredSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredThe Most Important Tech Company in America?One private company holds over $26 billion in government contracts tied to AI warfare and defense systems - an...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Integra LifeSciences Holdings Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Integra LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
